177Lu-DOTA-IBA治疗肿瘤骨转移的疗效与安全性:一项前瞻性临床试验
该前瞻性临床试验纳入69例骨转移参与者,评估177Lu-DOTA-IBA镇痛疗效与安全性。中位注射剂量1110 MBq,首次治疗、再治疗和总治疗的疼痛缓解率分别为82.5%、72.4%和79.3%。总疼痛闪烁反应发生率为16.8%,不良血液学事件总发生率为15%,68Ga-DOTA-IBA PET/CT显示27.1%的部分缓解影像学反应率。
要点
- 69例骨转移参与者接受177Lu-DOTA-IBA,首次治疗疼痛缓解率82.5%,再治疗72.4%,总治疗79.3%。
- KPS改善率首次治疗81.3%、再治疗60.6%、总治疗74.2%。
- 总疼痛闪烁反应发生率16.8%,不良血液学事件总发生率15%,影像学部分缓解率27.1%。
核心结论
- 177Lu-DOTA-IBA是一种有前景的骨靶向放射性药物,具有可观的疼痛缓解率和安全性,也可使部分骨转移参与者在影像学反应上获益。
研究设计与样本
- 前瞻性临床试验,纳入69例骨转移参与者,治疗前1周内行68Ga-DOTA-IBA PET/CT,治疗后8周内随访KPS、疼痛评分和血液生物标志物并重复68Ga-DOTA-IBA PET/CT评估影像学反应。
主要发现
- 69例参与者至少接受1剂177Lu-DOTA-IBA治疗,22例接受38次再注射剂量,共107次治疗,中位注射剂量1110 MBq。
- 首次治疗、再治疗和总治疗的疼痛缓解率分别为82.5%、72.4%和79.3%。
- 首次治疗、再治疗和总治疗的KPS改善率分别为81.3%、60.6%和74.2%。
- 疼痛闪烁反应(治疗后疼痛强度暂时加重)总发生率为16.8%。
- 68Ga-DOTA-IBA PET/CT对比分析显示部分缓解影像学反应率为27.1%,不良血液学事件总发生率为15%。
关键数值与推荐
- 影像学反应定义为完全缓解、部分缓解、稳定疾病和疾病进展。
- 后续治疗根据参与者同意和临床状况给予。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to evaluate the efficacy and safety of 177Lu-DOTA-IBA for pain palliation in participants with bone metastases and confirm its potential for treating bone metastasis. PATIENTS AND METHODS: Overall, 69 participants with bone metastases were included. 68Ga-DOTA-IBA PET/CT was performed within 1 week before treatment. Vital signs, blood markers, electrocardiogram, Karnofsky Performance Status (KPS), and pain scores were evaluated within 7 days before treatment. Postadministration of 177Lu-DOTA-IBA, participants' vital signs and general conditions were monitored. Follow-up evaluations of KPS, pain scores, and blood biomarkers were performed within 8 weeks. 68Ga-DOTA-IBA PET/CT was repeated to evaluate imaging responses at 8 weeks. Imaging responses were defined as complete response, partial response, stable disease, and disease progression. Subsequent treatments were administered based on participants' agreement and clinical conditions. RESULTS: Sixty-nine participants received at least 1 dose of 177Lu-DOTA-IBA treatment; 22 received 38 reinjected doses, totaling 107 treatments. The median injection dose of 177Lu-DOTA-IBA was 1110 MBq. The pain remission rates after first treatment, retreatment, and total treatment were 82.5%, 72.4%, and 79.3%, respectively. The improvement rates in KPS for first treatment, retreatment, and total treatment were 81.3%, 60.6%, and 74.2%, respectively. The total incidence of the pain flare reaction (temporary aggravation of pain intensity after treatment) was 16.8%. Comparative analysis of 68Ga-DOTA-IBA PET/CT showed a 27.1% rate of partial response imaging response. The total incidence of adverse hematological events was 15%. CONCLUSIONS: 177Lu-DOTA-IBA is a promising bone-seeking radiopharmaceutical with a considerable pain relief rate and safety. It also can benefit some participants with bone metastases in imaging response.
引用
- Xu T, Wang Y, Liu G, et al. Efficacy and Safety of 177Lu-DOTA-IBA in Tumor Bone Metastasis Treatment: A Prospective Clinical Trial. Clin Nucl Med. 2024. PMID: 39774154. doi:10.1097/RLU.0000000000005573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。